pyrazolanthrone has been researched along with imatinib mesylate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, SP; Chen, YC; Lee, WR; Shen, SC; Yang, LL | 1 |
| Changlong, Z; Guangwei, Z; Xiaochuan, S; Xiaohui, X; Xuenong, H; Yanfeng, X | 1 |
| Chang, SP; Chen, YC; Huang, HM; Lee, WR; Shen, SC | 1 |
| Jiao, B; Li, D; Liao, L; Liu, M; Liu, P; Ren, R; Wang, P; Xia, Z; Xiao, X; Zhang, X | 1 |
6 other study(ies) available for pyrazolanthrone and imatinib mesylate
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Imatinib mesylate induction of ROS-dependent apoptosis in melanoma B16F0 cells.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Benzamides; Flavonoids; Flow Cytometry; Imatinib Mesylate; Imidazoles; Melanoma, Experimental; Membrane Potentials; Mice; Mitochondria; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Reactive Oxygen Species | 2011 |
The Role of Platelet-Derived Growth Factor Receptor in Early Brain Injury Following Subarachnoid Hemorrhage.
Topics: Animals; Anthracenes; Antineoplastic Agents; Brain Edema; Brain Injuries; Caspase 3; Disease Models, Animal; Double-Blind Method; Enzyme Inhibitors; Gene Expression Regulation; Hippocampus; Imatinib Mesylate; In Situ Nick-End Labeling; Male; Platelet-Derived Growth Factor; Rats; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; RNA, Messenger; Subarachnoid Hemorrhage | 2016 |
Nilotinib induction of melanogenesis via reactive oxygen species-dependent JNK activation in B16F0 mouse melanoma cells.
Topics: Animals; Anthracenes; Antioxidants; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Enzyme Activation; Imatinib Mesylate; MAP Kinase Kinase 4; Melanins; Melanocytes; Melanoma, Experimental; Mice; Mitochondria; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species | 2018 |
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anthracenes; Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzamides; Cell Line, Tumor; Dasatinib; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Pyrimidines; Radiation Chimera; Random Allocation; RNA Interference; RNA, Small Interfering; Signal Transduction; Triazoles | 2020 |